| Recruitment status | Preinitiation |
| Unique ID issued by UMIN | UMIN000000660 |
| Receipt No. | R000000797 |
| Scientific Title | Development of new strategy for end stage dilated cardiomyopathy, a combination of left ventricular assist device and aoutologous myoblast sheets |
| Date of disclosure of the study information | 2007/04/01 |
| Last modified on | 2021/01/27 (Ver. 3) |
| Basic information | ||
| Public title | Development of new strategy for end stage dilated cardiomyopathy, a combination of left ventricular assist device and aoutologous myoblast sheets | |
| Acronym | A combination of left ventricular assist device and aoutologous myoblast sheets for end stage dilated cardiomyopathy | |
| Scientific Title | Development of new strategy for end stage dilated cardiomyopathy, a combination of left ventricular assist device and aoutologous myoblast sheets | |
| Scientific Title:Acronym | A combination of left ventricular assist device and aoutologous myoblast sheets for end stage dilated cardiomyopathy | |
| Region |
|
|
| Condition | ||
| Condition | End stage dilated cardiomyopathy patients who need LVAS | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Development of establishment of the methods utilizing aoutologous myoblast sheets cultured from skeletal muscle in the combination with left ventricular assist system (LVAS) against end stage dilated cardiomyopathy. The safety and the efficacy are tested. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Adverse events |
| Key secondary outcomes | Caridac function |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |||||
| No. of arms | 1 | ||||
| Purpose of intervention | Treatment | ||||
| Type of intervention |
|
||||
| Interventions/Control_1 | Culture of autologous skeltal myoblasts and engineering myoblast sheets. Transplantation of the myoblast sheets to the heart in the combination with LVAS implantation. | ||||
| Interventions/Control_2 | |||||
| Interventions/Control_3 | |||||
| Interventions/Control_4 | |||||
| Interventions/Control_5 | |||||
| Interventions/Control_6 | |||||
| Interventions/Control_7 | |||||
| Interventions/Control_8 | |||||
| Interventions/Control_9 | |||||
| Interventions/Control_10 | |||||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | End stage dilated cardiomyopathy
Requiring LVAS |
|||
| Key exclusion criteria | Severe skeletal muscle disease
Cancer Severe infection Alcoholic or drug addiction in recent six months Pregnancy Others (doctors dicision) |
|||
| Target sample size | 6 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Osaka University Graduate school of medicine | ||||||
| Division name | Cardiovascular surgery | ||||||
| Zip code | |||||||
| Address | 2-2 Yamadaoka Suita city, Osaka | ||||||
| TEL | 06-6879-3154 | ||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Osaka University Graduate school of medicine | ||||||
| Division name | Cardiovascular surgery | ||||||
| Zip code | |||||||
| Address | 2-2 Yamadaoka Suita city, Osaka | ||||||
| TEL | 06-6879-3154 | ||||||
| Homepage URL | |||||||
| matsumg@surg1.med.osaka-u.ac.jp | |||||||
| Sponsor | |
| Institute | Osaka University Graduate school of medicine, Cardiovascular surgery |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Preinitiation | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000000797 |